Delivery Order SPE2DB25D3001-SPE2DB25FQVBC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xeljanz XR 11 mg tablets in a quantity of 30-tablet units, with a contract ceiling value of $13,740.06. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract is scheduled for ultimate completion on September 12, 2025, and will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units, with a ceiling value of $5,651.30. This is a firm fixed-price delivery order with a completion deadline of September 12, 2025, and represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $46,432.78 and is scheduled for completion by June 2, 2025. The contract carries no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to compete in open federal procurement. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 6, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units, with a ceiling value of $6,576.04 and an ultimate completion date of May 7, 2025. This is a firm fixed price delivery order with no set-aside designation, competed through open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $3,198.50, was competitively awarded without set-aside designation and is scheduled for completion by August 22, 2025. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Xeljanz XR 11 mg tablets in a quantity of 30 units, with a ceiling value of $3,198.50. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The order is scheduled for completion by September 22, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Xeljanz XR 11 mg tablets in a quantity of 30 units, with a ceiling value of $92,797.95. This firm fixed-price delivery order is scheduled for completion by September 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a non-competitive set-aside procurement and is classified as a child contract,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units, with a contract ceiling value of $20,594.48. This firm fixed-price delivery order, which is not set-aside, represents a competitively awarded transaction under the company's existing indefinite delivery contract with DLA Troop Support Medical. The place of performance is located in Conshohocken, Pennsylvania, with an...
- The Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $12,570.58, represents a non-competitive, non-set-aside procurement and is scheduled for completion by August 26, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Xeljanz XR 11 mg tablets in a quantity of 30 units. This competitively awarded, non-set-aside contract has a ceiling value of $8,389.85 and is structured as a firm fixed price delivery order with an ultimate completion date of August 8, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB25D3001Indefinite Delivery Contract
- SPE2DB25D3001-SPE2DB25FQVBCDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units, with a ceiling value of $5,969.33. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 8, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the vendor's demonstrated capability to compete in open federal procurement processes. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications, vaccines, medical devices, and healthcare commodities to support military and veteran healthcare systems. The parent IDC serves as a flexible vehicle enabling the company to fulfill pharmaceutical requirements for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems across multiple therapeutic domains and regions globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.0k | 8/7/25 |